- Home
- STXS vs CRVO Comparison
STXS vs CRVO Comparison
Compare STXS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- CRVO
- Stock Information
- Founded
- STXS 1990
- CRVO 2001
- Country
- STXS United States
- CRVO United States
- Employees
- STXS N/A
- CRVO N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- STXS Health Care
- CRVO Health Care
- Exchange
- STXS Nasdaq
- CRVO Nasdaq
- Market Cap
- STXS 173.5M
- CRVO 160.4M
- IPO Year
- STXS 2004
- CRVO N/A
- Fundamental
- Price
- STXS $2.10
- CRVO $9.58
- Analyst Decision
- STXS Strong Buy
- CRVO Strong Buy
- Analyst Count
- STXS 2
- CRVO 6
- Target Price
- STXS $4.50
- CRVO $53.67
- AVG Volume (30 Days)
- STXS 332.6K
- CRVO 78.8K
- Earning Date
- STXS 11-11-2024
- CRVO 11-12-2024
- Dividend Yield
- STXS N/A
- CRVO N/A
- EPS Growth
- STXS N/A
- CRVO N/A
- EPS
- STXS N/A
- CRVO N/A
- Revenue
- STXS $25,143,000.00
- CRVO $10,066,550.00
- Revenue This Year
- STXS $1.16
- CRVO $54.67
- Revenue Next Year
- STXS $55.65
- CRVO N/A
- P/E Ratio
- STXS N/A
- CRVO N/A
- Revenue Growth
- STXS N/A
- CRVO 116.29
- 52 Week Low
- STXS $1.51
- CRVO $5.85
- 52 Week High
- STXS $3.29
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- STXS 53.19
- CRVO 27.48
- Support Level
- STXS $1.96
- CRVO $9.31
- Resistance Level
- STXS $2.12
- CRVO $11.44
- Average True Range (ATR)
- STXS 0.12
- CRVO 0.90
- MACD
- STXS 0.01
- CRVO -0.23
- Stochastic Oscillator
- STXS 50.00
- CRVO 6.34
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.